Compare PCM & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCM | THAR |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 82.7M |
| IPO Year | N/A | 2022 |
| Metric | PCM | THAR |
|---|---|---|
| Price | $6.06 | $2.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.1K | ★ 369.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.88 | $0.95 |
| 52 Week High | $10.20 | $9.08 |
| Indicator | PCM | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 50.42 |
| Support Level | $6.09 | $2.20 |
| Resistance Level | $6.15 | $2.62 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 4.35 | 67.27 |
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.